The new capital will be deployed to scale commercialisation of the PathCrisp molecular diagnostics platform, augmenting manufacturing capacity for high-impact tests in human health
Bengaluru-based biotechnology startup CrisprBits has raised $3 million through founders, angels & family offices, bringing the company's valuation to $12 Million.
The current Pre-Series A funding round was led by Spectrum Impact, the family office of Rajendra Gogri, Chairman and Managing Director of Aarti Industries. The round also saw participation from the founders and existing investors including Vijay Alreja Family Office (VJ Technologies Group), an early supporter of CrisprBits, whose group company VJ Bio focuses on cell and gene therapy, aligning closely with CrisprBits’ CRISPR-driven innovation goals. The round additionally brought in new investors, including the promoter family of HBL Engineering, building upon the earlier funds raised from the founders, VJ Technologies Group and C-CAMP (Centre for Cellular and Molecular Platforms).
The new capital will be deployed to scale commercialisation of the PathCrisp molecular diagnostics platform, augmenting manufacturing capacity for high-impact tests in human health (e.g., Sickle Cell, Typhoid and Anti-Microbial Resistance), food safety, and animal health. The funding will also accelerate the development of a cutting-edge, CRISPR-driven strain engineering platform, starting with the optimisation of processes for biofuel production to address unmet industrial sustainability needs.
Vijay Chandru, CEO, CrisprBits, said, “Our focus has always been on attracting patient capital that shares our visionary goal: to Rewrite Biology and Reimagine the Planet. This funding round provides the fuel for that mission and our team of pioneering CRISPR scientists and results-driven commercial leadership. We are now perfectly positioned to not just launch our products and services in India, but to immediately scale to global markets, ensuring our innovation delivers high-quality, affordable solutions at a truly international scale.”
Mirik Gogri, Principal, Spectrum Impact Family Office, said, “Our family office is excited to invest in CrisprBits. Given our experience in the process industry, we see a clear opportunity for synthetic biology to unlock new industrial frontiers. CrisprBits' strategy is perfectly poised to deliver multidimensional impact: high-quality diagnostics hitting the market very soon, and the pioneering strain engineering that will enable a more cost-effective future for biochemicals and biofuels. CrisprBits is taking a powerful technology and turning it into immense commercial and societal value. We look forward to working closely with them through this partnership.”
Over the next six months, CrisprBits plans to expand its CRISPR-based diagnostic products into global markets, including Africa and Latin America. The company also plans to strengthen its operations by expanding infrastructure and production capabilities at its diagnostics manufacturing facility. Additionally, the company plans to build a proprietary AI-augmented strain engineering platform for sustainability solutions, including enhancing biofuel production.
